Aeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.com
by Michael Walen · The Markets DailyStockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report released on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Performance
Shares of NASDAQ AEZS opened at $3.90 on Friday. The stock has a market cap of $6.99 million, a P/E ratio of -0.26 and a beta of 1.55. The firm has a 50 day moving average price of $4.87 and a 200 day moving average price of $6.46. Aeterna Zentaris has a 52-week low of $3.96 and a 52-week high of $12.00.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
Further Reading
- Five stocks we like better than Aeterna Zentaris
- Why Are Stock Sectors Important to Successful Investing?
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- The Risks of Owning Bonds
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Consumer Staples Stocks, Explained
- Microsoft’s Targeted Upside Might Be Too Good to Ignore